Biological versus mechanical prostheses for aortic valve replacement


Por: Rodríguez-Caulo EA, Blanco-Herrera OR, Berastegui E, Arias-Dachary J, Souaf-Khalafi S, Parody-Cuerda G and Laguna G

Publicada: 1 feb 2023 Ahead of Print: 1 ene 2023
Resumen:
Objectives: Long-term real-world outcomes are critical for informing decisions about biological (Bio) or mechanical (Mech) prostheses for aortic valve replace-ment, particularly in patients aged between 50 and 65 years. The objective was to compare long-term survival and major adverse cardiac and cardiovascular events (ie, stroke, reoperation, and major bleeding) within this population.Methods: This was a multicenter observational study including all patients aged be-tween 50 and 65 years who underwent an aortic valve replacement because of se-vere isolated aortic stenosis between the years 2000 and 2018. A total of 5215 patients from 27 Spanish hospitals were registered with a follow-up of 15 years. Multivariable analyses, including a 2:1 propensity score matching (1822 Mech and 911 Bio) and competing risks analyses were applied.Results: Bio prostheses were implanted in 19% of patients (n = 992). No significant differences were observed between matched groups in long-term survival (hazard ratio [HR], 1.14; 95% confidence interval [CI], 0.88-1.47; P = .33). Stroke rates were higher for Mech prostheses, but not significant (HR, 0.72; 95% CI, 0.50-1.03; P = .07). Finally, higher rates of major bleeding were found in the Mech group (HR, 0.65; 95% CI, 0.49-0.87; P = .004), whereas reoperation was more frequent among the Bio group (HR, 3.04; 95% CI, 1.80-5.14; P < .001). Bio prostheses increased from 13% in the period from 2000 to 2008 to 24% in 2009 to 2018.Conclusions: Long-term survival was comparable among groups in patients be-tween 50 and 65 years of age. Mech prostheses were associated with a higher risk of major bleeding, whereas Bio prostheses entailed higher reoperation rates. Bio prostheses seem a reasonable choice for patients between 50 and 65 years in Spain. (J Thorac Cardiovasc Surg 2023;165:609-17)

Filiaciones:
Rodríguez-Caulo EA:
 Cardiovascular Surgery Department, Virgen de la Macarena University Hospital, Sevilla, Spain

Blanco-Herrera OR:
 Cardiovascular Surgery Department, La Fe University Hospital, Valencia, Spain

:
 Cardiovascular Surgery Department, Germans Trias I Pujol Hospital, Badalona, Spain

Arias-Dachary J:
 Cardiovascular Surgery Department, Reina Sofia University Hospital, Cordoba, Spain

Souaf-Khalafi S:
 Cardiovascular Surgery Department, Clinic University Hospital, Santiago de Compostela, Spain

Parody-Cuerda G:
 Cardiovascular Surgery Department, Virgen de la Macarena University Hospital, Sevilla, Spain

Laguna G:
 Cardiovascular Surgery Department, Clinic University Hospital, Valladolid, Spain
ISSN: 00225223





Journal of Thoracic and Cardiovascular Surgery
Editorial
Mosby Inc., United States, Estados Unidos America
Tipo de documento: Article
Volumen: 165 Número: 2
Páginas: 609
WOS Id: 000992307500001
ID de PubMed: 33712230

MÉTRICAS